Carcinoma, Neuroendocrine

"Carcinoma, Neuroendocrine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)

Descriptor ID	D018278
MeSH Number(s)	C04.557.465.625.650.240 C04.557.470.200.025.370 C04.557.580.625.650.240
Concept/Terms	Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Carcinomas, Neuroendocrine Neuroendocrine Carcinoma Neuroendocrine Carcinomas

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Neuroendocrine".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Germ Cell and Embryonal [C04.557.465]
Neuroectodermal Tumors [C04.557.465.625]
Neuroendocrine Tumors [C04.557.465.625.650]
Carcinoma, Neuroendocrine [C04.557.465.625.650.240]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Adenocarcinoma [C04.557.470.200.025]
Carcinoma, Neuroendocrine [C04.557.470.200.025.370]
Neoplasms, Nerve Tissue [C04.557.580]
Neuroectodermal Tumors [C04.557.580.625]
Neuroendocrine Tumors [C04.557.580.625.650]
Carcinoma, Neuroendocrine [C04.557.580.625.650.240]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Neuroendocrine".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Neuroendocrine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Neuroendocrine" by people in this website by year, and whether "Carcinoma, Neuroendocrine" was a major or minor topic of these publications.

Bar chart showing 26 publications over 12 distinct years, with a maximum of 5 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	1	0	1
2000	1	0	1
2002	1	0	1
2013	0	1	1
2014	1	0	1
2018	1	1	2
2019	2	0	2
2020	5	0	5
2021	1	0	1
2022	3	1	4
2023	2	2	4
2024	2	1	3

Below are the most recent publications written about "Carcinoma, Neuroendocrine" by people in Profiles.

Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N. Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. J Patient Rep Outcomes. 2024 12 19; 8(1):149.

View in: PubMed
Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 09 20; 42(27):3187-3195.

View in: PubMed
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.

View in: PubMed
Ahmed S, Wedekind MF, Del Rivero J, Raygada M, Lockridge R, Glod JW, Flowers C, Thomas BJ, Bernstein DB, Kapustina OB, Jain A, Miettinen M, Raffeld M, Xi L, Tyagi M, Kim J, Aldape K, Malayeri AA, Kaplan RN, Allen T, Vivelo CA, Sandler AB, Widemann BC, Reilly KM. Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants. Cancer Res Commun. 2023 12 06; 3(12):2468-2482.

View in: PubMed
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, F?hrer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 11 16; 389(20):1851-1861.

View in: PubMed
Venigalla T, Kalathil S, Bansal M, Morginstin M, Jorge V, Perosio P. An Unusual Case of Hemophagocytic Lymphohistiocytosis Associated with Mycobacterium chimaera or Large-Cell Neuroendocrine Carcinoma. Curr Oncol. 2023 03 21; 30(3):3529-3536.

View in: PubMed
Paterson C, Perrotti G, Mushtaq B, Heilman J, Fassler S. Mixed Adeno-Neuroendocrine Neoplasms: Two Cases, One Institution. CRSLS. 2023 Oct-Dec; 10(4).

View in: PubMed
Quaglia F, Krishn SR, Sossey-Alaoui K, Rana PS, Pluskota E, Park PH, Shields CD, Lin S, McCue P, Kossenkov AV, Wang Y, Goodrich DW, Ku SY, Beltran H, Kelly WK, Corey E, Klose M, Bandtlow C, Liu Q, Altieri DC, Plow EF, Languino LR. The NOGO receptor NgR2, a novel aV?3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Sci Rep. 2022 11 07; 12(1):18879.

View in: PubMed
Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na?ve RET-mutant medullary thyroid cancer. Future Oncol. 2022 Sep; 18(28):3143-3150.

View in: PubMed
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 08; 20(8):925-951.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement